Startups
Biocross
Biotechnology company developing blood-based biomarker assays for neurodegenerative disease assessment. Its e4Risk test detects the ApoE4 protein, a genetic-risk-associated biomarker relevant to Alzheimer’s disease, using routine laboratory analyzers. It also develops quantitative ApoE4 and other dementia biomarker tests. Test results support evaluation alongside other clinical information and do not establish an Alzheimer’s diagnosis on their own.